Acute cerebral infarction, also known as acute ischemic stroke, refers to the neurologic deficit syndrome caused by the ischemia and anoxic state in brain tissue. As a serious nervous system disease with high disability rate, high mortality rate and high incidence of complications, acute cerebral infarction brings heavy burden to our family and society. The key point of treatment is to open the occluded vessels and restore the blood flow as early as possible to save the ischemic penumbra. At present, the most effective treatments for hyperacute cerebral infarction mainly includes intravenous thrombolysis and intravascular intervention. Intravenous thrombolysis is the first choice and recommended by domestic and international guidelines. Most of the thrombolytic drugs are fibrinolytic enzyme activators, which can directly or indirectly activate fibrinolytic enzyme and degrade fibrin, so as to achieve the goal of thrombolysis. However, the recanalization rate of intravenous thrombolysis is low in patients with large vessel occlusive cerebral infarction. Intravascular therapy can directly observe thrombolysis and recanalization, improve recanalization rate and improve clinical prognosis, such as arterial thrombolysis, mechanical thrombectomy and so on. In recent years, domestic researchers have done a lot of exploration. The clinical research of intravenous thrombolysis and intravascular therapy is increasing gradually. This article makes a brief review of this, in order to find better clinical evidence and improve the quality of clinical medical practice. At the same time, it is found that there are still many problems, which limits the reference value of the results, such as the large differences in research methodology, the lack of clinical research on new thrombolytic drugs, the lack of unified specifications of mechanical thrombectomy technology, etc. We are looking forward to the further improvement.
DownLoad: